Drug Profile
Research programme: Alzheimer's disease gene therapy - Johnson & Johnson Innovation/Johnson & Johnson Innovative Medicine/University of Pennsylvania
Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Janssen Pharmaceuticals; Johnson & Johnson Innovation; University of Pennsylvania
- Developer Johnson & Johnson Innovation; Johnson & Johnson Innovative Medicine; University of Pennsylvania
- Class Antidementias; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 28 Feb 2022 No recent reports of development identified for research development in Alzheimer's-disease in USA (Parenteral)
- 05 Jan 2018 Johnson & Johnson Innovation, Janssen Pharmaceuticals and University of Pennsylvania sign a research collaboration agreement for the development of gene therapy for Alzheimer's disease